Invasive infection due to Candida krusei in immunocompromised patients not treated with fluconazole

Clinical Infectious Diseases

Volumn 20, Issue 2, 1995, Pages 342-347

  Iwen, Peter C ^a   Kelly, Dianne M ^a   Reed, Elizabeth C ^a   Hinrichs, Steven H ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE;

ADULT; AGED; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA KRUSEI; CANDIDIASIS; FEMALE; HUMAN; IMMUNE DEFICIENCY; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ABDOMINAL INJURIES; ADULT; AGED; BREAST NEOPLASMS; CANDIDIASIS; CHILD; CHILD, PRESCHOOL; FEMALE; FLUCONAZOLE; HUMAN; IMMUNOCOMPROMISED HOST; LEUKEMIA; LIVER DISEASES; MALE; MIDDLE AGE; RETROSPECTIVE STUDIES;

EID: 0028887667     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/clinids/20.2.342     Document Type: Article

References (35)

1. Fraser VJ, Jones M, Dunkel J, Storfer S, Medoff G, Dunagan WC. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis 1992; 15:414-21.
2. Harvey RL, Myers JP. Nosocomial fungemia in a large community teaching hospital. Arch Intern Med 1987; 147:2117-20.
3. Meunier F, Aoun M, Bitar N. Candidemia in immunocompromised patients. Clin Infect Dis 1992; 14(suppl 1):S120-5.
4. Odds FC. Candida and candidosis. 2nd ed. London: Bailliere Tindall, 1988:206-30.
5. Peters B, Bruce J, Frederick W. Changing patterns of fungemia in an inner city hospital [abstract no F-17], Abstracts of the 92nd General Meeting of the American Society for Microbiology 1992; 92:501.
6. Swerdloff JN, Filler SG, Edwards JE Jr. Severe candidal infections in neutropenic patients. Clin Infect Dis 1993; 17(suppl 2):S457-67.
7. Meunier-Carpentier F, Kiehn TE, Armstrong D. Fungemia in the immunocompromised host: changing patterns, antigenemia, high mortality. Am J Med 1981;71:363-70.
8. McQuillen DP, Zingman BS, Meunier F, Levitz SM. Invasive infections due to Candida krusei: report of ten cases of fungemia that include three cases of endophthalmitis. Clin Infect Dis 1992; 14:472-8.
9. Merz WG, Karp JE, Schron D, Saral R. Increased incidence of fungemia caused by Candida krusei. J Clin Microbiol 1986;24:581-4.
10. Mcllroy MA. Failure of fluconazole to suppress fungemia in a patient with fever, neutropenia, and typhlitis [letter], J Infect Dis 1991;163:420-1.
11. Abrahamsen TG, Widing E, Glomstein A, Gaustad P. Disseminated fungal disease resistant to fluconazole treatment in a child with leukemia. Scand J Infect Dis 1992;24:391-3.
12. Persons DA, Laughlin M, Tanner D, Perfect J, Gockerman JP, Hathorn JW. Fluconazole and Candida krusei fungemia [letter], N Engl J Med 1991:325:1315.
13. Schuler U, Ehninger G. Prophylactic fluconazole and Candida krusei infections [letter], N Engl J Med 1992;326:892.
14. Samonis G, Rolston K, Karl C, Miller P, Bodey GP. Prophylaxis of oropharyngeal candidiasis with fluconazole. Rev Infect Dis 1990; I2(suppl 3):S369-73.
15. Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991;325; 1274-7.
16. Dermoumi H. In vitro susceptibility of yeast isolates from the blood to fluconazole and amphotericin B. Chemotherapy 1992;38:112-7.
17. Morace G, Manzara S, Dettori G. In vitro susceptibility of 119 yeast isolates to fluconazole, 5-fluorocytosine, amphotericin B, and keto- conazole. Chemotherapy 1991;37:23-31.
18. Goodman JL., Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992;326:845-51.
19. Winston DJ, Chandrasekar PH, Lazarus HM, et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia: results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med 1993; 118:495-503.
20. Shadomy S, Espinel-lngroff A., Cartwright RY. Laboratory studies with antifungal agents: susceptibility tests and bioassays. In: Lennette EH. Balows A, Hausier WJ Jr. Shadomy HJ, eds. Manual of clinical microbiology. 4th eds. Washington, DC: American Society for Microbiology, 1985:991-9.
21. Goldman M, Pottage JC Jr. Weaver DC. Candida krusei fungemia: report of 4 cases and review of the literature. Medicine (Baltimore) 1993;72:143-50.
22. Walsh TJ, Lee JW. Prevention ofinvasive fungal infections in patients with neoplastic diseases. Clin Infect Dis 1993; 17(suppl 2):S468-80.
23. Gaines JD, Remington JS. Disseminated candidiasis in the surgical patient. Surgery 1972;72:730-6.
24. Iwen PC., Reed EC, Armitage JO, et al. Nosocomial invasive aspergillosis in lymphoma patients treated with bone marrow or peripheral stem cell transplants. Infect Control Hosp Epidemiol 1993; 14: 131-9.
25. Khoo SH, Bond J, Denning DW. Administering amphotericin B—a practical approach. J Antimicrob Chemother 1994:33:203-13.
26. Safe LM, Safe SH, Subden RE. Morris DC. Sterol content and polyene antibiotic resistance in isolates of Candida krusei. Candida parakru- sei, and Candidatropicalis. Can J Microbiol 1977;23:398-401.
27. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. Proposed standard M-27-P. Villanova, PA: NCCLS, 1992.
28. Wingard JR. Dick JD, Merz WG, Sandford GR, Saral R, Burns WH. Pathogenicity of Candida tropicalis and Candida albicans after gastrointestinal inoculation in mice. Infect Immun 1980:29:808-13.
29. Luna MA, Tortoledo ME. Histologic identification and pathologic patterns of disease caused by Candida. In: Bodey GP, ed. Candidiasis: pathogenesis, diagnosis, and treatment. 2nd ed. New York: Raven Press, 1993:21-42.
30. Walsh TJ. Merz WG. Pathologic features in the human alimentary tract associated with invasiveness of Candida tropicalis. Am J Clin Pathol 1986;85:498-502.
31. Schimpff SC, Greene WH, Young VM, et al. Infection prevention in acute nonlymphocytic leukemia: laminar air flow room reverse isolation with oral, nonabsorbable antibiotic prophylaxis. Ann Intern Med 1975;82:351-8.
32. Shepp DH, Klosterman A, Siegel MS, Meyers JD. Comparative trial of ketoconazole and nystatin for prevention of fungal infection in neutropenic patients treated in a protective environment. J Infect Dis 1985;152:1257-63.
33. Paya CV. Fungal infections in solid-organ transplantation. Clin Infect Dis 1993; 16:677-88.
34. Francis P, Walsh TJ. Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy. Clin Infect Dis 1992;15:1003-18.
35. Myerowitz RL. The pathology of opportunistic infections. New York: Raven Press, 1983:95-114.